American Society of Clinical Oncology (ASCO)

Kelun-Biotech to Present the Final OS Analysis of Sacituzumab Tirumotecan (Sac-TMT) from the OptiTROP-Lung03 Study

2026-03-18 22:31 3579

CHENGDU, China, March 18, 2026 /PRNewswire/ -- The 2026 European Lung Cancer Congress (ELCC) will be held in Copenhagen, Denmark, from March 25 to 28, 2026 (local time). At this congress, the final OS analysis from the pivotal study (OptiTROP-Lung03) of sacituzumab tirumotecan (sac-TMT, also know...

Connecting the World, Empowering the Future

2026-03-17 16:47 2068

CAC2026 Opened in Shanghai, Building a Global Ecosystem for the Entire Crop Inputs Industry Chain SHANGHAI, March 17, 2026 /PRNewswire/ -- The 26th China International Agrochemical & Crop Protection Exhibition (CAC2026) grandly opened onMarch 17 at National Exhibition and Convention Center (Shan...

Registrational Phase III AMPLIFY trial: Target number of participants achieved

2026-03-10 21:02 3200

SYDNEY, March 10, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the Phase III A...

CARsgen Therapeutics Announces 2025 Annual Results

2026-03-06 20:03 7517

SHANGHAI, March 6, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its 2025 Annual Results. Business Highlights * Cash and cash equivalents were around RMB1,123 million as of Decemb...

Akeso and INOVIO Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)

2026-03-04 21:52 4655

* Collaboration will evaluate Akeso's cadonilimab in combination with INOVIO's INO-5412 (INO-5401 plus INO-9012) as a potential treatment for glioblastoma (GBM), the most common and aggressive form of brain cancer * Novel combination therapy will be studied as part of the Phase II adaptive pl...

ImmVira's Oncolytic Product MVR-T3011 Expanded to BCG-Naïve Bladder Cancer Patients for the First Time with Clinical Data Presented at the 2026 ASCO GU Conference

2026-02-27 08:00 4617

SUZHOU, China, Feb. 26, 2026 /PRNewswire/ -- Intravesical BCG is the standard of care (SOC) for BCG-naïve high-risk non-muscle-invasive bladder cancer (NMIBC) patients. However, the scarcity of BCG products has become a global phenomenon, and coupled with the side effects of BCG therapy itself,me...

Co-PSMA: Cu-64 SAR-bisPSMA more than doubled prostate cancer lesion and patient detection vs. Ga-68 PSMA-11 in head-to-head trial

2026-02-16 22:03 7758

HIGHLIGHTS * Abstract outlining key findings from the Co-PSMA Investigator-Initiated Trial (IIT) has been released. * The study was led by Prof Louise Emmett at St Vincent's Hospital Sydney, and the abstract was accepted for oral presentation at the upcoming European Association of Urology (...

CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 (PD-1/VEGF/CTLA-4) to Advance into Phase II Clinical Trial

2026-02-16 08:10 6774

* CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA)to initiate a Phase II clinical trial inpatients with advanced solid tumors. This marks a significant milestone in the global development of thi...

Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for First Line Treatment of HER2-positive Breast Cancer

2026-02-13 08:00 6089

SAN FRANCISCO and SUZHOU, China, Feb. 12, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent",HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ...

Akeso Receives Fifth Breakthrough Therapy Designation from NMPA for Ivonescimab in First-Line Treatment of Advanced Biliary Tract Cancer

2026-02-06 10:26 7196

HONG KONG, Feb. 5, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to announce that ivonescimab, its global first-in-class bispecific antibody targeting PD-1 and VEGF, has been granted its fifth Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of the National Medic...

HanchorBio Accelerates Global Clinical Footprint with Multiple Oral and Poster Presentations in Q1 2026

2026-02-05 17:09 6869

Sustained execution and high-impact data across HanchorBio's next-generation immuno-oncology portfolio to be featured at ASCO-GI, AACR-IO, ESMO-TAT, ICNHO, and WOC TAIPEI and SHANGHAI and SAN FRANCISCO, Feb. 4, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechno...

Singapore Airshow 2026 Milestone Edition: 20 Years of Shaping the Aerospace Landscape as Asia-Pacific Drives Global Growth

2026-02-01 19:35 6846

SINGAPORE, Feb. 1, 2026 /PRNewswire/ -- Singapore Airshow 2026, organised and managed by Experia Events Pte Ltd, will take place from 3 to 8 February 2026 at the Changi Exhibition Centre, marking its 10th edition and 20 years of contribution to the global aerospace, defence and space sectors. The...

Henlius Showcases "Globalisation 2.0" Strategy and Mid-to-Long-Term Innovation Blueprint at JPM 2026

2026-01-16 21:00 5647

SAN FRANCISCO, Jan. 16, 2026 /PRNewswire/ -- The 44th J.P.Morgan Healthcare Conference (JPMHC) was successfully held inSan Francisco, the United States, fromJanuary 12 to 15. As one of the most influential annual events in the global healthcare sector, JPM serves as a key platform for the capital...

Kelun-Biotech Showcases Innovative Achievements and Future Development Strategy at the 44th Annual JPM Healthcare Conference

2026-01-16 02:30 10351

CHENGDU, China, Jan. 16, 2026 /PRNewswire/ -- From January 12 to 15, 2026, the 44th J.P. Morgan Healthcare Conference (JPMHC) was held in San Francisco, California, USA. Dr. Ge Michael, President and CEO of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990....

Shanghai Electric Showcases "The Power of Integration" at WFES 2026, with Full-Scenario Energy Solutions for the Middle East

2026-01-15 14:24 5195

ABU DHABI, UAE, Jan. 15, 2026 /PRNewswire/ -- Shanghai Electric (SEHK: 2727, SSE: 601727) made a high-profile appearance at the World Future Energy Summit (WFES) 2026, which opened today at the Abu Dhabi National Exhibition Center. At the summit, the company showcased its full-scenario energy sol...

Head-to-Head Real-World Data: Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer

2026-01-14 11:54 5646

HONG KONG, Jan. 13, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced the presentation of a real-world study at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), comparing cadonilimab plus chemotherapy against a PD-1 inhibitor plus chemotherapy for th...

Gene Solutions Concludes Successful ESMO Asia Congress 2025 with AI-Powered Multi-Omics Liquid Biopsy Symposium and Two Best Poster Awards

2025-12-20 11:14 6787

SINGAPORE, Dec. 20, 2025 /PRNewswire/ -- Gene Solutions, a pioneering genetic testing company, announced key achievements at the European Society for Medical Oncology (ESMO) Asia Congress 2025—held inSingapore on December 5–7. Highlights included a full-house symposium, seven scientific abstracts...

Singapore Airshow 2026 Marks 10th Edition with New Frontiers in Aviation and Space

2025-12-18 19:41 6799

SINGAPORE, Dec. 18, 2025 /PRNewswire/ -- Singapore Airshow, one of the most influential international aerospace and defence exhibition, will return from 3 -8 February 2026 at the Changi Exhibition Centre. Marking two decades of defining the future of flight, the biennial event will once again bring...

NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO

2025-12-11 14:12 2621

* Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients with advanced or metastatic solid tumors, including those who have relapsed or are refractory to checkpoint inhibitors, a multi-billion dollar pillar of cancer care, hampered by widespread resistance * The study a...

MALAYSIA REMAINS COMMITTED TO ACCELERATE TRANSFORMATIVE SOLUTIONS FOR A SUSTAINABLE AND INCLUSIVE FUTURE

2025-12-06 00:41 4543

BELÉM, Brazil, Dec. 6, 2025 /PRNewswire/ -- The Malaysia Pavilion concluded its participation atCOP30 in Belém, Brazil, reaffirming the nation's commitment to accelerate transformative solutions for a sustainable and inclusive future. Over the two weeks, the Pavilion served as a vibrant hub for m...

1234